Exploring the Latest Data on Optimal pulmonary arterial hypertension (PAH) Treatment Approaches is organized by Medscape, LLC.

CME / ABIM MOC / CE Released: 12/23/2020
Valid for credit through: 12/23/2021

Accreditation:
For Physicians
Medscape, LLC designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit(s)™ . Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 0.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.

Goal Statement:
The goal of this activity is to discuss recent abstracts presented at the 2020 CHEST annual meeting, addressing the management of patients with pulmonary arterial hypertension (PAH).

Learning Objectives:
Upon completion of this activity, participants will:
• Have increased knowledge regarding the
? Benefits of combination therapy over monotherapy for newly diagnosed PAH
? Expectations of triple therapy based on real-world data
? Impact of PAH-specific therapy on right ventricular function
? Novel endpoints being investigated to better understand the impact of PAH treatments